- Home
- OFIX vs EBS Comparison
OFIX vs EBS Comparison
Compare OFIX & EBS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | OFIX | EBS |
|---|---|---|
| Founded | 1987 | 1998 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Medical/Dental Instruments | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 473.3M | 423.6M |
| IPO Year | 1998 | 2006 |
Fundamental Metrics
Financial Performance| Metric | OFIX | EBS |
|---|---|---|
| Price | $9.73 | $8.24 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 5 | 1 |
| Target Price | ★ $17.25 | $12.00 |
| AVG Volume (30 Days) | 484.3K | ★ 728.7K |
| Earning Date | 05-05-2026 | 04-30-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | 29.39 | ★ 125.83 |
| EPS | N/A | ★ 0.07 |
| Revenue | ★ $822,312,000.00 | $742,900,000.00 |
| Revenue This Year | $6.13 | $1.29 |
| Revenue Next Year | $6.22 | N/A |
| P/E Ratio | ★ N/A | $113.57 |
| Revenue Growth | ★ 2.85 | N/A |
| 52 Week Low | $9.13 | $5.62 |
| 52 Week High | $16.99 | $14.06 |
Technical Indicators
Market Signals| Indicator | OFIX | EBS |
|---|---|---|
| Relative Strength Index (RSI) | 38.45 | 46.88 |
| Support Level | $9.13 | $7.76 |
| Resistance Level | $12.72 | $8.54 |
| Average True Range (ATR) | 0.63 | 0.46 |
| MACD | 0.01 | -0.06 |
| Stochastic Oscillator | 28.54 | 34.78 |
Price Performance
Historical ComparisonAbout OFIX Orthofix Medical Inc. (DE)
Orthofix Medical Inc. is a medical device company delivering orthopedic and spine solutions to healthcare providers. The company has two reportable segments: Global Spine and Global Limb Reconstruction. The Global Spine segment offers bone growth therapies, spinal implants, biologics, and enabling technologies used in spinal procedures. The Global Limb Reconstruction segment provides products and solutions for limb deformity correction, limb lengthening, fracture management, and limb preservation, supported by digital technologies. It generates the majority of its revenue from the Global Spine segment.
About EBS Emergent Biosolutions Inc.
Emergent BioSolutions Inc offers public health products to the government and healthcare providers. Company operates in three segments namely Commercial Product, MCM Products, and Services segment. The Commercial Product Segment consisting of Nasal Spray; the MCM Products Segment consisting of Anthrax-MCM products, Smallpox-MCM products and Other Products and the Services Segment consisting of Bioservices portfolio. Geographically, the company operates in United States, Canada, and Others. It derives maximum revenue from United states. The company's products include: NARCAN Nasal Spray, KLOXXADO Nasal Spray, ACAM2000, ANTHRASIL, BAT, BioThrax, CNJ-016, raxibacumab injection, Ebanga, and others.